• Publications
  • Influence
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.
Tuberculosis continues to kill 1·4 million people annually. During the past 5 years, an alarming increase in the number of patients with multidrug-resistant tuberculosis and extensivelyExpand
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Summary Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functionalExpand
Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.
OBJECTIVE Nine out of ten tuberculosis deaths occur in tuberculosis-burdened countries, particularly Sub Saharan Africa. In these setting mortality has not been fully described. We describe theExpand
Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas
Significance Tuberculosis (TB) granulomas represent sites of both bacterial containment and tissue pathology. Macrophage killing of Mycobacterium tuberculosis (Mtb) in granulomas to contain infectionExpand
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responsesExpand
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
KRAS is a driver mutation for malignant transformation. It is found in 30% of all cancers and in 90% of pancreatic cancers. The identification of small molecules selectively inhibiting KRAS mutantsExpand
Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette-Guérin vaccination.
BACKGROUND Bacille Calmette-Guérin (BCG) is the world's most widely distributed vaccine, used against tuberculosis (TB), in cancer immunotherapy, and in autoimmune diseases due to itsExpand
Tumor-infiltrating lymphocytes (TILs) from patients with glioma
ABSTRACT Tumor-infiltrating lymphocytes (TILs) may represent a viable source of T cells for the biological treatment of patients with gliomas. Glioma tissue was obtained from 16 patients, tumor cellExpand
T-Cell Therapy: Options for Infectious Diseases
The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis andExpand
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
BACKGROUND New tuberculosis (TB) drug treatment regimens are urgently needed. This study evaluated the potential of the histone deacetylase inhibitors (HDIs) valproic acid (VPA) and suberoylanilideExpand
...
1
2
3
4
...